Stay updated on Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.

Latest updates to the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe study record describes a completed Phase 2 trial of oral azacitidine combined with pembrolizumab for metastatic melanoma, including its two treatment groups, participant criteria, and measured outcomes. It also lists the study’s dates, locations, and investigators.SummaryDifference61%

- Check16 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov revision as v3.8.0 instead of v3.7.2.SummaryDifference0.3%

- Check23 days agoChange DetectedAn NIH site-wide banner announces updates and FAQs about a terminology transition, stating that “Super Intelligence” is replacing “Artificial Intelligence” in some NIH content. The study page itself continues to show a 403 error.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2. The page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, indicating the record is inaccessible; the screen shows the 403 header and standard error-page navigation.SummaryDifference21%

Stay in the know with updates to Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.